Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder

Phase 3 ◽

Term Efficacy ◽

Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2010;57:766–73

European Urology ◽

10.1016/j.eururo.2010.02.037 ◽

2010 ◽

Vol 57 (6) ◽

pp. e57

Author(s):

Tommaso Cai ◽

Lorenzo Giuseppe Luciani ◽

Gianni Malossini

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

European Urology ◽

10.1016/j.eururo.2009.12.024 ◽

2010 ◽

Vol 57 (5) ◽

pp. 766-773 ◽

Cited By ~ 225

Author(s):

Richard J. Sylvester ◽

Maurizio A. Brausi ◽

Wim J. Kirkels ◽

Wolfgang Hoeltl ◽

Fernando Calais Da Silva ◽

...

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Reply to Tomasso Cai, Lorenzo Giuseppe Luciani and Gianni Malossini’s Letter to the Editor re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2010;57:766–73

European Urology ◽

10.1016/j.eururo.2010.02.038 ◽

2010 ◽

Vol 57 (6) ◽

pp. e58-e59

Author(s):

Richard J. Sylvester ◽

Maurizio A. Brausi ◽

Ziya Kirkali ◽

Theo M. de Reijke

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Letter To The Editor ◽

Re: Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

European Urology ◽

10.1016/j.eururo.2011.03.040 ◽

2011 ◽

Vol 59 (6) ◽

pp. 1065

Author(s):

Donald L. Lamm

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Re: Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin Plus Isoniazid in Patients With Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

The Journal of Urology ◽

10.1016/j.juro.2011.05.038 ◽

2011 ◽

Vol 186 (3) ◽

pp. 840-840

Author(s):

David P. Wood

Keyword(s):

High Risk ◽

Urothelial Carcinoma ◽

Phase 3 ◽

Term Efficacy ◽

Re: Side Effects of bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

The Journal of Urology ◽

10.1016/j.juro.2014.09.034 ◽

2014 ◽

Vol 192 (6) ◽

pp. 1641-1641

Author(s):

David P. Wood

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Phase 3 ◽

Full Dose ◽

LONG-TERM EFFICACY RESULTS OF EORTC GU GROUP STUDY 30911 COMPARING EPIRUBICIN, BACILLUS CALMETTE- GUERIN (BCG), AND BCG PLUS ISONIAZID IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 BLADDER CARCINOMA

The Journal of Urology ◽

10.1016/s0022-5347(08)61710-3 ◽

2008 ◽

Vol 179 (4S) ◽

pp. 583-583

Author(s):

Richard Sylvester ◽

Maurizio Brausi ◽

Wolfgang Hoeltl ◽

Philip Powell ◽

Peter Whelan ◽

...

Keyword(s):

High Risk ◽

Bladder Carcinoma ◽

Term Efficacy

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

European Urology ◽

10.1016/j.eururo.2013.07.021 ◽

2014 ◽

Vol 65 (1) ◽

pp. 69-76 ◽

Cited By ~ 122

Author(s):

Maurizio Brausi ◽

Jorg Oddens ◽

Richard Sylvester ◽

Aldo Bono ◽

Cees van de Beek ◽

...

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Phase 3 ◽

Full Dose ◽

LONG-TERM EFFICACY RESULTS OF EORTC GU GROUP STUDY 30911 COMPARING EPIRUBICIN, BACILLUS CALMETTEGUERIN (BCG), AND BCG PLUS ISONIAZID IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER

European Urology Supplements ◽

10.1016/s1569-9056(08)60904-5 ◽

2008 ◽

Vol 7 (3) ◽

pp. 298 ◽

Cited By ~ 5

Author(s):

R.J. Sylvester ◽

M.A. Brausi ◽

W. Hoeltl ◽

P.H. Powell ◽

P. Whelan ◽

...

Keyword(s):

High Risk ◽

Papillary Carcinoma ◽

Term Efficacy ◽

Adjuvant vs. progression-triggered treatment with gemcitabine after radical cystectomy in platinum-ineligible patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (AUO-AB 22-00): Long-term follow-up of a randomized multicenter phase 3 trial

European Urology ◽

10.1016/s0302-2838(21)01203-3 ◽

2021 ◽

Vol 79 ◽

pp. S1152-S1153

Author(s):

J. Heinzelbecker ◽

N. Spieler ◽

M. Kühn ◽

C. Fischer ◽

B. Volkmer ◽

...

Keyword(s):

Urothelial Carcinoma ◽

Radical Cystectomy ◽

Phase 3 ◽

Multicenter Phase ◽

Long Term Follow Up ◽